Best-in-class
anticancer
drug
HLB develops the ‘Rivoceranib’, the Best-in-class
targeted therapy for unmet medical needs in cancer.
targeted therapy for unmet medical needs in cancer.
Leader of Global
Pharma
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
First-in-class drugs with continuous innovation and challenges.
IR Letter
-
Apealea completes Pre-NDA meeting
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th... -
Immunomic Therapeutics, EPIVAX, Pha...
- Agreement of COVID-19 Vaccine Joint DevelopmentAccording to a foreign press reported at 5 o'clock in the morning, thre...
Press Release
-
Replicate Bioscience and ITI Form C...
Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technolo... -
Immunomic Therapeutics to Present a...
Immunomic Therapeutics, Inc. will present preclinical data on its investigational nucleic acid platform, UNITE (Univer...